Medical Devices Middle East

Middle East Automated Insulin Delivery Systems Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Middle East Automated Insulin Delivery Systems Market Industry Trends and Forecast to 2034: Segmented by (Component, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Middle East · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $123.0 Mn Placeholder estimate
Estimate 2025 $145.0 Mn 4.1% of the global market
Projected 2034 $638.2 Mn 340.2% Adds $493.2 Mn over 9 forecast years
CAGR 2025–2034 17.9% Faster than 91% of 193 Medical Devices markets here
Key players 6 +1
  • Middle East is 4.07% of the global market.
  • Among regions, the largest is North America at $2.00 Bn.
  • Fastest growing: Africa at 18.2% a year.
  • Middle East ranks 4th of 6 by size among regions.

Market size projection

Middle East

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$493.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Automated Insulin Delivery Systems Market market size by year, Middle East
YearMarket sizeChange that yearSince 2025
2024 (estimate) $123.0 Mn — —
2025 (base) $145.0 Mn +$22.0 Mn —
2026 (forecast) $170.9 Mn +$26.0 Mn +17.9%
2027 (forecast) $201.5 Mn +$30.6 Mn +39%
2028 (forecast) $237.6 Mn +$36.1 Mn +63.9%
2029 (forecast) $280.1 Mn +$42.5 Mn +93.2%
2030 (forecast) $330.3 Mn +$50.1 Mn +127.8%
2031 (forecast) $389.4 Mn +$59.1 Mn +168.6%
2032 (forecast) $459.1 Mn +$69.7 Mn +216.7%
2033 (forecast) $541.3 Mn +$82.2 Mn +273.3%
2034 (forecast) $638.2 Mn +$96.9 Mn +340.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Middle East Automated Insulin Delivery Systems Market Analysis at a glance
Market size, 2025$145.0 Mn placeholder estimate
Forecast, 2034$638.2 Mn placeholder estimate
Growth (CAGR), 2025–203417.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsComponent, type and end user (see all)
Key playersMedtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and 1 more (see all)
Active clinical trials13 in Middle EastSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Middle East Automated Insulin Delivery Systems Market Analysis Executive Summary

Automated insulin delivery systems link an insulin pump with a glucose sensor and software that adjusts insulin doses automatically.

Key segments of the automated Insulin Delivery Systems market include component (Insulin Pumps, CGM Sensors and Control Algorithms) and type (Hybrid Closed Loop and Advanced Hybrid Closed Loop).

Bar chart: Middle East Automated Insulin Delivery Systems market size, 2024–2034, placeholder estimates. $123.0 Mn in 2024, $145.0 Mn in 2025 and $638.2 Mn in 2034, 17.9% CAGR.
Middle East Automated Insulin Delivery Systems market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Middle East Automated Insulin Delivery Systems Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the automated Insulin Delivery Systems market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the automated Insulin Delivery Systems market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Automated Insulin Delivery Systems Market in Middle East

The automated Insulin Delivery Systems market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Automated Insulin Delivery Systems Market in Middle East

Automated Insulin Delivery Systems in Middle East: rules, payment and research

In some of the countries we cover here, medical devices are regulated by SFDA (Saudi Arabia)⁠[1], EDE (UAE)⁠[2], Ministry of Public Health (Qatar)⁠[3] and AMAR (Israel)⁠[4]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)⁠[5], mandatory health insurance (UAE)⁠[6], public care and compulsory insurance (Qatar)⁠[3] and four health funds (Israel)⁠[4]. ClinicalTrials.gov lists 13 studies on Automated Insulin Delivery Systems that are recruiting, active or about to start in Middle East.⁠[7]

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Emirates Drug Establishment. Checked 14 Nov 2026.

[3] Ministry of Public Health, Qatar. Checked 19 Nov 2026.

[4] Israel Ministry of Health. Checked 19 Nov 2026.

[5] Council of Health Insurance. Checked 14 Nov 2026.

[6] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.

[7] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how automated Insulin Delivery Systems products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Middle East.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Automated Insulin Delivery Systems right now, from free public sources.

Clinical trials

13 active trials in UAE, Saudi Arabia, Israel, Yemen, Jordan, Lebanon, Qatar, Syria, Palestine and Iraq

Recruiting, about to start, or running now. Counted across the 10 countries we report on in Middle East.

Top trial sponsors (worldwide)

  1. Sanofi 9 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Eli Lilly and Company 9 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Novo Nordisk A/S 9 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Insulet Corporation 5 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Medtronic 5 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Diabetes (adults), % of adults (WHO)
CountryValueYear
Iraq25.52022
Israel7.92022
Jordan18.42022
Lebanon19.42022
Palestine19.72022
Qatar25.82022
Saudi Arabia20.82022
Syria21.72022
UAE26.12022
Yemen18.32022
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Automated Insulin Delivery Systems in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Automated Insulin Delivery Systems market in Middle East?
Placeholder estimate: about $145.0 Mn in 2025, rising to about $638.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Automated Insulin Delivery Systems market in Middle East growing?
Placeholder estimate: about 17.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Automated Insulin Delivery Systems market report cover?
The report splits the market by component (Insulin Pumps, CGM Sensors, Control Algorithms), type (Hybrid Closed Loop, Advanced Hybrid Closed Loop) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Automated Insulin Delivery Systems market?
Key players include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and Beta Bionics.
What is driving the Automated Insulin Delivery Systems market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market.
How many clinical trials on Automated Insulin Delivery Systems are running in Middle East?
13 studies are recruiting, active or about to start in Middle East, counted across the 10 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.
How much research is published on Automated Insulin Delivery Systems?
PubMed lists 373 papers on Automated Insulin Delivery Systems added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Middle East

See all

Related on diabetes and remote monitoring and wearables

See the topic